Kymera CEO Sells $6 Million in Stock After Significant Share Price Increase

Nello Mainolfi, the CEO of Kymera Therapeutics (KYMR), sold $6 million worth of stock on July 7, 2026. The sale followed a 170% total return for the company's shares over the past year and was conducted under a Rule 10b5-1 trading plan.

By Jonathan Ponciano · Motley Fool · July 12, 2026, 20:37 UTC

Kymera CEO Sells $6 Million in Stock After Significant Share Price Increase

Tickers: $KYMR

Topics: insider trading Kymera Therapeutics SEC filing

Read the full article at Motley Fool

More World news

Lufax Reports Third Quarter 2026 Net Loss Amid Rising Credit Impairment Costs Motley Fool · November 12, 2026, 18:15 UTC
Avantor Reports Return to Organic Revenue Growth in Third Quarter 2026 Motley Fool · November 12, 2026, 18:15 UTC
MGP Ingredients Rebrands to Sempreon and Announces Strategic Shift Toward Ready-to-Drink Products Motley Fool · November 12, 2026, 18:15 UTC
ICON Reports Q3 2026 Revenue of $2 Billion and Accelerating Book-to-Bill Ratio Motley Fool · November 12, 2026, 18:15 UTC
Beachbody (BODi) Reduces Annual Revenue Breakeven to $125 Million Amid Strategic Pivot Motley Fool · November 12, 2026, 18:15 UTC
Standard Nuclear Reports $577.2 Million Contract Backlog and Targets 2027 DOE Authorization Seeking Alpha · November 12, 2026, 18:10 UTC
Nuwellis Reports Q3 2026 Revenue of $2.2 Million and Improved Operating Loss Motley Fool · November 12, 2026, 18:09 UTC
Nebius Group Reports Strong Revenue Growth Amidst Capacity Delays and Increased Capital Expenditure Motley Fool · November 12, 2026, 18:11 UTC
Pelagos Insurance Reports Q3 2026 Earnings with Increased Gross Premiums Written Motley Fool · November 12, 2026, 18:11 UTC
Sprott Physical Gold Trust USD Reports Q3 Net Income of $508.82 Million Seeking Alpha · November 12, 2026, 18:07 UTC